Nautilus Biotech S.A.
Nautilus Biotech S.A., headquartered in France, is a pioneering company in the biotechnology sector, specialising in the development of innovative protein-based therapeutics. Founded in 2015, Nautilus has rapidly established itself as a leader in the biopharmaceutical industry, focusing on advanced drug discovery and development processes that leverage cutting-edge technologies. With a strong presence in Europe and expanding operations globally, Nautilus Biotech is renowned for its unique approach to protein engineering, which enhances the efficacy and safety of therapeutic proteins. The company’s core offerings include bespoke protein design and optimisation services, setting it apart in a competitive market. Nautilus has achieved significant milestones, including strategic partnerships and successful product launches, solidifying its position as a key player in the biotechnology landscape.
DitchCarbon Score
How does Nautilus Biotech S.A.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Nautilus Biotech S.A.'s score of 21 is higher than 86% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Nautilus Biotech S.A.'s reported carbon emissions
Nautilus Biotech S.A., headquartered in France, currently does not have publicly available carbon emissions data for the most recent year, nor specific reduction targets or climate commitments outlined in their initiatives. Without concrete figures or defined goals, it is challenging to assess their carbon footprint or climate strategy. However, the absence of emissions data suggests that the company may still be in the early stages of formalising its climate commitments or reporting practices. As the biotechnology industry increasingly prioritises sustainability, it is essential for companies like Nautilus Biotech to establish clear emissions reduction targets and engage in transparent reporting to align with global climate goals.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Nautilus Biotech S.A. is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
